267 related articles for article (PubMed ID: 32815870)
1. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Haas DW; Podany AT; Bao Y; Swindells S; Chaisson RE; Mwelase N; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Baker P; Fletcher CV
Pharmacogenet Genomics; 2021 Jan; 31(1):17-27. PubMed ID: 32815870
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Pham MM; Podany AT; Mwelase N; Supparatpinyo K; Mohapi L; Gupta A; Samaneka W; Omoz-Oarhe A; Langat D; Benson CA; Chaisson RE; Swindells S; Fletcher CV
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0238521. PubMed ID: 35943252
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N; Scarsi KK; Baker P; Smeaton LM; Podany AT; Olefsky M; Woolley E; Barr E; Pham M; Mawlana S; Supparatpinyo K; Gatechompol S; Jalil EM; Gadama L; Badal-Faesen S; Van Schalkwyk M; Kayama C; Belaunzaran-Zamudio PF; Godfrey C; Cohn SE; Mngqibisa R; Haas DW;
Pharmacogenet Genomics; 2023 Aug; 33(6):126-135. PubMed ID: 37306344
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
Haas DW; Mngqibisa R; Francis J; McIlleron H; Robinson JA; Kendall MA; Baker P; Mawlana S; Badal-Faesen S; Angira F; Omoz-Oarhe A; Samaneka WP; Denti P; Cohn SE;
Pharmacogenet Genomics; 2022 Jan; 32(1):24-30. PubMed ID: 34369424
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
[TBL] [Abstract][Full Text] [Related]
8. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Bertrand J; Verstuyft C; Chou M; Borand L; Chea P; Nay KH; Blanc FX; Mentré F; Taburet AM;
J Infect Dis; 2014 Feb; 209(3):399-408. PubMed ID: 23990572
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R; Nightingale S; Brey N; Albertyn CH; Kellermann TA; Taljaard JJ; Esterhuizen TM; Sinxadi PZ; Decloedt EH
Clin Infect Dis; 2022 Aug; 75(3):399-405. PubMed ID: 34882770
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Gausi K; Wiesner L; Norman J; Wallis CL; Onyango-Makumbi C; Chipato T; Haas DW; Browning R; Chakhtoura N; Montepiedra G; Aaron L; McCarthy K; Bradford S; Vhembo T; Stranix-Chibanda L; Masheto GR; Violari A; Mmbaga BT; Aurpibul L; Bhosale R; Nevrekhar N; Rouzier V; Kabugho E; Mutambanengwe M; Chanaiwa V; Nyati M; Mhembere T; Tongprasert F; Hesseling A; Shin K; Zimmer B; Costello D; Jean-Philippe P; Sterling TR; Theron G; Weinberg A; Gupta A; Denti P;
Clin Pharmacol Ther; 2021 Apr; 109(4):1034-1044. PubMed ID: 32909316
[TBL] [Abstract][Full Text] [Related]
11. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Podany AT; Pham M; Sizemore E; Martinson N; Samaneka W; Mohapi L; Badal-Faesen S; Dawson R; Johnson JL; Mayanja H; Lalloo U; Whitworth WC; Pettit A; Campbell K; Phillips PPJ; Bryant K; Scott N; Vernon A; Kurbatova EV; Chaisson RE; Dorman SE; Nahid P; Swindells S; Dooley KE; Fletcher CV
Clin Infect Dis; 2022 Sep; 75(4):560-566. PubMed ID: 34918028
[TBL] [Abstract][Full Text] [Related]
12. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
Podany AT; Leon-Cruz J; Hakim J; Supparatpinyo K; Omoz-Oarhe A; Langat D; Mwelase N; Kanyama C; Gupta A; Benson CA; Chaisson RE; Swindells S; Fletcher CV;
J Antimicrob Chemother; 2021 Feb; 76(3):718-721. PubMed ID: 33241266
[TBL] [Abstract][Full Text] [Related]
13. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P;
J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel KD; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E
PLoS One; 2011; 6(12):e27810. PubMed ID: 22162992
[TBL] [Abstract][Full Text] [Related]
15. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ;
Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
Neary M; Lamorde M; Olagunju A; Darin KM; Merry C; Byakika-Kibwika P; Back DJ; Siccardi M; Owen A; Scarsi KK
Clin Pharmacol Ther; 2017 Sep; 102(3):529-536. PubMed ID: 28187506
[TBL] [Abstract][Full Text] [Related]
18. Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Sundell J; Bienvenu E; Janzén D; Birgersson S; Äbelö A; Ashton M
Clin Pharmacol Ther; 2020 Jul; 108(1):73-80. PubMed ID: 32017035
[TBL] [Abstract][Full Text] [Related]
19. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
[TBL] [Abstract][Full Text] [Related]
20. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
